Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
Julián Panés,Yoram Bouhnik,Walter Reinisch,Jaap Stoker,Stuart A. Taylor,Daniel C. Baumgart,Silvio Danese,Steve Halligan,B. Marincek,Celso Matos,Laurent Peyrin-Biroulet,Jordi Rimola,Gerhard Rogler,G. Van Assche,Sandro Ardizzone,A. Ba-Ssalamah,M.A. Bali,Davide Bellini,Livia Biancone,Fabiana Castiglione,Robert Ehehalt,Roberto Grassi,Torsten Kucharzik,Francesca Maccioni,Giovanni Maconi,Fernando Magro,J. Martín-Comín,Giovanni Morana,Doug Pendse,Shaji Sebastian,Alberto Signore,D. Tolan,Jeroen A. W. Tielbeek,Dominik Weishaupt,B. Wiarda,Andrea Laghi +35 more
TLDR
ECCO and ESGAR scientific societies jointly elaborated a consensus to establish standards for imaging in IBD using magnetic resonance imaging, computed tomography, ultrasonography, and including also other radiologic procedures such as conventional radiology or nuclear medicine examinations for different clinical situations.About:
This article is published in Journal of Crohn's and Colitis.The article was published on 2013-08-01 and is currently open access. It has received 549 citations till now.read more
Citations
More filters
Journal ArticleDOI
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more
TL;DR: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available and future studies are needed to determine how these targets will change disease course and patients’ quality of life.
Journal ArticleDOI
Crohn's disease
TL;DR: An physician-oriented overview of Crohn's disease in adults is provided, ranging from epidemiology and cause to clinical diagnosis, natural history, patient stratification and clinical management, and ending with an overview of emerging therapies and future directions for research.
Journal ArticleDOI
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.
Fernando Magro,Paolo Gionchetti,Rami Eliakim,Sandro Ardizzone,Alessandro Armuzzi,Manuel Barreiro-de Acosta,Johan Burisch,Krisztina Gecse,Ailsa Hart,Pieter Hindryckx,Cord Langner,Jimmy K. Limdi,Gianluca Pellino,Edyta Zagórowicz,Tim Raine,Marcus Harbord,Florian Rieder +16 more
TL;DR: This research presents a meta-analyses of Gastroenterology and Hepatology at the cellular and molecular level, which shows clear trends in the development of immune-oncology-metabolical pathways towards “clinically checkpoints”.
Journal ArticleDOI
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
Christian Maaser,Andreas Sturm,Stephan R. Vavricka,Torsten Kucharzik,Gionata Fiorino,Vito Annese,Emma Calabrese,Daniel C. Baumgart,Dominik Bettenworth,Paula Borralho Nunes,Johan Burisch,Fabiana Castiglione,Rami Eliakim,Pierre Ellul,Yago Gonzalez-Lama,Hannah Gordon,Steve Halligan,Konstantinos Katsanos,Uri Kopylov,Paulo Gustavo Kotze,Eduards Krustins,Andrea Laghi,Jimmy K. Limdi,Florian Rieder,Jordi Rimola,Stuart A. Taylor,Damian Tolan,Patrick F. van Rheenen,Bram Verstockt,Jaap Stoker +29 more
TL;DR: Christian Maaser, a Andreas Sturm,b Stephan R. Vavricka,c Torsten Kucharzik,d Gionata Fiorino,e Vito Annese,f Emma Calabrese,f Daniel C. Baumgart,h Dominik Bettenworth,i Paula Borralho Nunes,j, Johan Burisch,k, Fabiana Castiglione,l Rami Eliakim,m Pierre Ellul,n Yago Gonz
Journal ArticleDOI
Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.
Marco Pennazio,Cristiano Spada,Rami Eliakim,Martin Keuchel,Andrea May,Chris J. J. Mulder,Emanuele Rondonotti,Samuel N. Adler,Joerg G. Albert,Peter Baltes,Federico Barbaro,Christophe Cellier,Jean Pierre Charton,Michel Delvaux,Edward J. Despott,Dirk Domagk,Amir Klein,Mark E. McAlindon,Bruno Rosa,Georgina Rowse,David S Sanders,Jean Christophe Saurin,Reena Sidhu,Jean-Marc Dumonceau,Cesare Hassan,Ian M. Gralnek +25 more
TL;DR: This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy and addresses the roles of small-bowel capsule endoscope and device-assisted enteroscopy for diagnosis and treatment ofsmall-bowe disorders.
References
More filters
Book
Health Risks from Exposure to Low Levels of Ionizing Radiation:: BEIR VII Phase 2
TL;DR: Health risks from exposure to low levels of ionizing radiation : BEIR VII Phase 2 , Health risks from Exposure to low Levels of Ionizing radiation: BEIR VIII Phase 2, شاپور اهواز.
Journal ArticleDOI
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frederic Colombel,William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Remo Panaccione,Stefan Schreiber,Dan Byczkowski,Ju Li,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Epidemiology and Natural History of Inflammatory Bowel Diseases
TL;DR: It has been proposed that only aggressive therapeutic approaches, based on treatment of early recurrent lesions in asymptomatic individuals, have a significant impact on progression of these chronic diseases.
Journal Article
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
Ulrich Beuers,Kirsten Muri Boberg,Roger W. Chapman,Olivier Chazouillères,Pietro Invernizzi,David Jones,Frank Lammert,Albert Parés,Michael Trauner +8 more
TL;DR: The clinical care for patients with cholestatic liver diseases has advanced considerably during recent decades thanks to growing insight into pathophysiological mechanisms and remarkable methodological and technical developments in diagnostic procedures as well as therapeutic and preventive approaches.
Related Papers (5)
Inflammatory Bowel Disease Diagnosed with US, MR, Scintigraphy, and CT: Meta-analysis of Prospective Studies
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollón,Axel Dignass,Vito Annese,Herbert Tilg,Gert Van Assche,James O. Lindsay,Laurent Peyrin-Biroulet,Garret Cullen,Marco Daperno,Torsten Kucharzik,Florian Rieder,Sven Almer,Alessandro Armuzzi,Marcus Harbord,Jost Langhorst,Miquel Sans,Yehuda Chowers,Gionata Fiorino,Pascal Juillerat,Gerassimos J. Mantzaris,Fernando Rizzello,Stephan R. Vavricka,Paolo Gionchetti +22 more